银河galaxySpike RBD蛋白详情
类型 |
靶点 |
表达宿主 |
标签 |
野生型 |
SARS-CoV-2 N protein |
Insect cell |
His |
E.coli |
SARS-CoV-2 S-RBD |
Insect cell |
His |
Mammalian cell |
His/mFc |
SARS-CoV-2 S-ECD |
Insect cell |
His/Flag |
Mammalian cell |
SARS-CoV-2 S1 |
Mammalian cell |
His |
SARS-CoV-2 RBD-sc-dimerNew
|
Mammalian cell |
/ |
N Protein:核衣壳蛋白全长,序列由银河galaxy设计并优化。
下游应用:体外诊断抗体制备,体外诊断试剂盒生产。
S-RBD:S蛋白受体结合区,序列由银河galaxy设计,结合蛋白3D构象分析,预测更准确。
下游应用:功能检测,中和抗体制备,体外诊断试剂盒生产。
S-ECD:S蛋白膜外区全长。
下游应用:功能检测,体外诊断抗体制备。
S RBD-sc-dimer:RBD结构域中由二硫键链接二聚体。
下游应用:在MERS,SARS,COVID-19中均可构建RBD-sc-dimer结构,可用于MERS,SARS,COVID-19等疫苗制备。
靶点 |
应用 |
纯度 |
QC |
S-RBD His tag |
IgM/IgG kit with Anti-His antibody |
>90% |
SDS-PAGE, WB, ELISA binding against ACE2 |
S-RBD mFc tag |
IgM/IgG kit with Anti-Mouse antibody |
Spike RBD蛋白,His tag
Lane M1: Protein Marker, GenScript, Cat. No. M00516
Lane M2: Protein Marker, GenScript, Cat. No. M00521
Lane 1: BSA (2.00 μg)
Lane 2: RBD Protein (Reducing condition, 2.00 μg)
Lane 3: RBD Protein (Non-reducing condition, 2.00 μg)
Lane 4: RBD Protein (Reducing condition)
Lane 5: RBD Protein (Non-reducing condition)
Primary antibody: Mouse-anti-His mAb (GenScript, Cat.No. A00186)
银河galaxy生产的S-RBD(his tag)蛋白SDS-PAGE纯度>90%,纯度高。
采用ELISA方法检测S-RBD(his tag)蛋白与ACE2的结合活性,EC50<100ng/ml,活性好。
TCR-抗原亲和性和免疫原性筛选
个性化癌症疫苗(PCV)
个性化疫苗药效筛选
采用ELISA方法检测3个不同批次的S-RBD(his tag)蛋白与ACE2的结合活性,3个批次蛋白活性基本一致。
Spike RBD蛋白,mFc tag
Lane M1: Protein Marker, TaKaRa, Cat. No. 3452
Lane M2: Protein Marker, GenScript, Cat. No. M00521
Lane 1: Reducing condition
Lane 2: Non-reducing condition
Lane P: Mouse IgG1, Kappa (Sigma, Cat.No.M9269) as a positive
control
Primary antibody: MonoRab™ Mouse IgG (76F10), mAb, Rabbit (GenScript,
Cat.No. Cat. V90301)
银河galaxy生产的S-RBD(mFc tag)蛋白SDS-PAGE纯度>90%,纯度高。
采用ELISA方法检测S-RBD(mFc tag)蛋白与ACE2的结合活性,EC50<100ng/ml,活性好。
Spike RBD-sc-dimer蛋白
注:Lane M: Merker
Lane 1: Reducing condition
Lane 2: Non-reducing condition
银河galaxy生产RBD-sc-dimer,SDS-PAGE检测纯度达90%,SEC-HPLC测试纯度达97.9%,纯度高。
采用ELISA方法检测RBD-sc-dimer与ACE2蛋白结合活性,EC50低至16.8ng/ml,活性高。
Lianpan Dai, Tianyi Zheng, Kun Xu, A universal design of
betacoronavirus vaccines against COVID-19, MERS and SARS.Cell.August,6,2020.